These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38619722)

  • 1. Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy.
    Hannah KL; Nemlekar PM; Green CR; Norman GJ
    Adv Ther; 2024 Jun; 41(6):2299-2306. PubMed ID: 38619722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of continuous glucose monitoring on emergency department visits and all-cause hospitalization rates among Medicaid beneficiaries with type 2 diabetes treated with multiple daily insulin or basal insulin therapy.
    Hirsch IB; Burugapalli BS; Brandner L; Poon Y; Frazzitta M; Godavarthi L; Virdi N
    J Manag Care Spec Pharm; 2024 Oct; 30(10-b Suppl):S21-S29. PubMed ID: 39347973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis.
    Garg SK; Hirsch IB; Repetto E; Snell-Bergeon J; Ulmer B; Perkins C; Bergenstal RM
    Diabetes Obes Metab; 2024 Nov; 26(11):5202-5210. PubMed ID: 39263872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
    Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
    Dalal MR; Kazemi M; Ye F; Xie L
    Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
    Kalirai S; Duan R; Liu D; Reed BL
    J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
    Yeaw J; Lee WC; Aagren M; Christensen T
    J Manag Care Pharm; 2012; 18(1):21-32. PubMed ID: 22235952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of self-monitoring blood glucose in nonintensively managed type 2 diabetes.
    Kerr D; Duncan I; Repetto E; Maroun R; Wu A; Perkins C; Bergman G; Giorgino F
    Am J Manag Care; 2023 Dec; 29(12):670-675. PubMed ID: 38170484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin.
    Kim JY; Ilham S; Alshannaq H; Pollock RF; Ahmed W; Norman GJ; Jin SM; Kim JH
    J Med Econ; 2024; 27(1):1245-1252. PubMed ID: 39275990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
    Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
    Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
    Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
    J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes.
    Norman GJ; Paudel ML; Parkin CG; Bancroft T; Lynch PM
    Diabetes Technol Ther; 2022 Jul; 24(7):520-524. PubMed ID: 35230158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and Outcomes Comparison of Diabetes Technology Usage Among People With Type 1 or 2 Diabetes Using Rapid-Acting Insulin.
    Vallarino CR; Wong-Jacobson SH; Benneyworth BD; Meadows ES
    J Diabetes Sci Technol; 2023 Mar; 17(2):439-448. PubMed ID: 34654339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
    Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flash CGM associated with event reduction in nonintensive diabetes therapy.
    Miller E; Kerr MSD; Roberts GJ; Nabutovsky Y; Wright E
    Am J Manag Care; 2021 Nov; 27(11):e372-e377. PubMed ID: 34784145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.